Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, and Daniel A. Goldstein, MD, of the Rabin Medical Center, discuss global challenges in cancer care, including treating patients in areas lacking resources, and cancer drug price disparities (Abstract LBA6500).

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Caroline Robert, MD, PhD, of Gustave Roussy and Paris-Sud University, discuss study findings on pembrolizumab and the overall survival benefit for patients with advanced disease (Abstract 9503).

Multiple Myeloma

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial (Italian Language Version)

Antonio Palumbo, MD, of the University of Torino, discusses in Italian this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4).

To see the English language version of this video, please click here.

Kidney Cancer

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I and II studies of nivolumab given to patients with metastatic renal cell carcinoma, including long-term overall survival and potential predictors of benefit (Abstract 4507).

Lung Cancer

Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006).

To see the English language version of this discussion, click here.

Oct

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial (Italian Language Version)

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version)

TIL Therapy Plus Pembrolizumab for Advanced Melanoma

Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction

Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer

Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors

Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC